Search
Alpha Cognition Inc
ACOGAdd to Watchlist
7.890USD
+0.100+1.28%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
171.80MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.28%
5 Days
+21.38%
1 Month
+27.67%
6 Months
+21.38%
Year to Date
+21.38%
1 Year
-26.19%
Key Figures
7.840Open
8.000High
51.97KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.24%Turnover Ratio
7.790Prev. Close
7.350Low
302.74KTurnover
LossP/E Static
2.74P/B
0.00%Div Yield TTM
-43.14%ROA
11.54052wk High
1.43Volume Ratio
-14.64MNet Profit
21.74MShares
-1.3591EPS TTM
2.37Beta
-51.74%ROE
4.50052wk Low
8.34%Amplitude
92.16%Gross Margin
171.80MMarket Cap
6.70Reward/Risk
4.20%Risk Rate
TradingKey Stock Score of Alpha Cognition Inc
Currency: USD Updated: 2026-07-02Key Insights
Alpha Cognition Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 83 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alpha Cognition Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Alpha Cognition Inc Highlights
StrengthsRisks
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.22M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 10.22M.
Undervalued
The company’s latest PE is -5.81, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.46M shares, increasing 11.83% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 59.02K shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
14.667
Target Price
+115.37%
Upside Space
Alpha Cognition Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alpha Cognition Inc Info
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Ticker SymbolACOG
CompanyAlpha Cognition Inc
CEOMcfadden (Michael E)
Websitehttps://www.alphacognition.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52926.200
+83.700 (+0.16%)
29618.600
+307.200 (+1.05%)
7503.800
+32.300 (+0.43%)
14964.000
+161.000 (+1.09%)
69664.000
+1516.000 (+2.23%)
6380.300
+27.500 (+0.43%)
68.433
+0.089 (+0.13%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.190
+55.280 (+1.34%)
FAQs
What is the current price of Alpha Cognition Inc (ACOG)?
The current price of Alpha Cognition Inc (ACOG) is 7.89.
What is the symbol of Alpha Cognition Inc?
The ticker symbol of Alpha Cognition Inc is ACOG.
What is the 52-week high of Alpha Cognition Inc?
The 52-week high of Alpha Cognition Inc is 11.54.
What is the 52-week low of Alpha Cognition Inc?
The 52-week low of Alpha Cognition Inc is 4.50.
What is the market capitalization of Alpha Cognition Inc?
The market capitalization of Alpha Cognition Inc is 171.55M.
Is Alpha Cognition Inc (ACOG) currently rated as Buy, Hold, or Sell?
According to analysts, Alpha Cognition Inc (ACOG) has an overall rating of Buy, with a price target of 14.67.
What is the Earnings Per Share (EPS TTM) of Alpha Cognition Inc (ACOG)?
The Earnings Per Share (EPS TTM) of Alpha Cognition Inc (ACOG) is -1.17.